protein expression
PreclinicalBiologic
protein expression is one of 5 biologic programs targeting Transient Ischemic Attack. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Transient Ischemic Attack
#DrugCompanyPhaseTrials
1Prevacid
TakedaApproved
Statin
Bristol-Myers SquibbPhase 3
Victoza
Novo NordiskPreclinical
Sanchitongshu
XXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Preclinical
protein expression
UUniversity Hospital, Caen
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for protein expression. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital, Caen